menu
    • menu
    [{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Acorn Bioventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Public Offering","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Acorn Bioventures","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Acorn Bioventures"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2-MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for ALRN-6924

    Menu

    ALRN-6924

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of ...

                            Details : ALRN-6924 is an MDM2/MDMX inhibitor that leverages Aileron’s proprietary peptide drug technology. The primary endpoint of the Phase 1b open-label trial was duration and incidence of severe neutropenia in cycle 1.

                            Brand Name : ALRN-6924

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 21, 2023

                            Lead Product(s) : ALRN-6924

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human ...

                            Details : The primary endpoints are duration and incidence of severe neutropenia (Grade 4) in cycle 1. Secondary endpoints include the chemoprotective effect of ALRN-6924 on chemotherapy-induced alopecia, as well as other hematologic and non-hematologic toxicities...

                            Brand Name : ALRN-6924

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 30, 2022

                            Lead Product(s) : ALRN-6924

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Pati...

                            Details : Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mut...

                            Brand Name : ALRN-6924

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 01, 2022

                            Lead Product(s) : ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with ...

                            Details : ALRN-6924, first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biom...

                            Brand Name : ALRN-6924

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 29, 2022

                            Lead Product(s) : ALRN-6924,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Muta...

                            Details : Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities.

                            Brand Name : ALRN-6924

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 19, 2022

                            Lead Product(s) : ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924,Paclitaxel

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Pr...

                            Details : Non-clinical data demonstrated principle that ALRN-6924 can temporarily arrest cell cycle in human scalp hair follicles and their stem cells also ALRN-6924-induced cell cycle arrest protected hair follicles from paclitaxel-induced toxicity and irreversib...

                            Brand Name : ALRN-6924

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 10, 2022

                            Lead Product(s) : ALRN-6924,Paclitaxel

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Acti...

                            Details : ALRN-6924 is first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21

                            Brand Name : ALRN-6924

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 07, 2021

                            Lead Product(s) : ALRN-6924

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924,Topotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in...

                            Details : A precision medicine-based chemoprotective agent, ALRN-6924 is designed to selectively activate p53 in normal cells, thereby upregulating p21, which pauses cell cycle in normal cells but not in p53-mutated cancer cells.

                            Brand Name : ALRN-6924

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 16, 2021

                            Lead Product(s) : ALRN-6924,Topotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Presents Initial Findings from Ongoing Healthy Volunteer Study of ALRN-6924 at ISEH 50th ...

                            Details : Initial findings from an ongoing study demonstrated that a 0.3 mg/kg dose of ALRN-6924 has been very well tolerated and resulted in p53-mediated induction of the cell cycle inhibitor p21 in normal bone marrow cells in healthy volunteers.

                            Brand Name : ALRN-6924

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 27, 2021

                            Lead Product(s) : ALRN-6924,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aileron Therapeutics

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALRN-6924,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Acorn Bioventures

                            Deal Size : $35.9 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aileron Therapeutics Announces Completion of $35.9 Million Registered Direct Offering

                            Details : Aileron is developing ALRN-6924 as a novel medicine to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy’s effects against cancer ...

                            Brand Name : ALRN-6924

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            January 11, 2021

                            Lead Product(s) : ALRN-6924,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Acorn Bioventures

                            Deal Size : $35.9 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth